AOD-9604 vs Tesamorelin
Both are sold for belly fat. One failed its phase 2 trials and one is an approved drug. Which is which, and does the failed one add anything?
Reviewed by the amino101 editorial team. , first published .
AOD-9604 and tesamorelin are both pitched for fat loss and both descend from growth hormone biology, which is where the resemblance stops. AOD-9604 is a modified copy of amino acids 176 to 191 of growth hormone, built to keep the fat burning signal of the hormone without its growth or glucose effects. It does not bind the growth hormone receptor and does not raise IGF-1. Its one real test, a 24 week phase 2b program in more than 500 obese adults, found no meaningful weight loss versus placebo, and Metabolic Pharmaceuticals stopped development in 2007. Tesamorelin is a stabilized version of the full growth hormone releasing hormone that makes the pituitary release growth hormone. It was approved by the FDA in 2010 as Egrifta for excess abdominal fat in HIV associated lipodystrophy, on the strength of two phase 3 trials with over 800 participants showing visceral fat down about 15 to 18 percent over 26 weeks. The honest framing is that one of these has negative human data and the other has positive human data, and the market sells them side by side anyway. Both are prohibited by WADA. This is an educational comparison, not a recommendation.
| AOD-9604 | Tesamorelin | |
|---|---|---|
| Typical dosage | 250 to 500 mcg | 1 to 2 mg |
| Frequency | once daily | once daily |
| Route | Subcutaneous, Oral | Subcutaneous |
| Half-life | short, likely under an hour in plasma; not well characterized in published work | 26 to 38 minutes in plasma |
| Cycle | 8 to 12 weeks | ongoing; reassess at 3 to 6 months with IGF-1 and waist measurements |
| Research level | Limited research | Extensively studied |
| Human trials | Randomized trials | Approved drug |
| Status | Not approved as a drug anywhere; failed phase 2 obesity trials. Has GRAS status as a food ingredient in the US. Prohibited by WADA under S0. | FDA approved (Egrifta) for HIV-associated lipodystrophy; off-label otherwise |
| Effects timeline | no acute effect to notice; any change in body composition is judged at 8 to 12 weeks, and the trials found none | IGF-1 rise 2 to 4 weeks, waist and visceral fat change 12 to 26 weeks |
Key differences
AOD-9604 vs Tesamorelin dosage
Dosage patterns reported in research and community protocols, by goal. Taken from each compound page. Not a prescription.
| Goal | Dosage | Frequency |
|---|---|---|
| Standard fat loss protocol, community | 300 mcg | once daily, morning |
| Higher end | 500 mcg | once daily, before fasted cardio |
| Lower end or stacked | 250 mcg | once daily |
| Oral, as used in the trials | 1 mg | once daily |
| Goal | Dosage | Frequency |
|---|---|---|
| Approved dose | 2 mg | once daily |
| Reduced dose for cost or side effects | 1 mg | once daily |
| Stacked with a GHRP | 1 to 2 mg | once daily before bed, with 100 mcg ipamorelin |
| Maintenance after fat loss | 1 mg | once daily, or 2 mg on alternating days |
Convert any of these to syringe units in the dosage calculator.
Side effects compared
- ▲Injection site redness or itching
- ▲Headache, reported occasionally
- ▲Mild nausea after a dose
- ▲Transient lightheadedness
- ▲Water retention has been reported anecdotally but did not appear in trials
- ▲Injection site redness, itching, bruising, or irritation
- ▲Joint pain and stiffness
- ▲Swelling in the hands and feet, carpal tunnel symptoms
- ▲Elevated blood glucose in susceptible people
- ▲Headache or flushing
Which should you choose?
AOD-9604 fits almost no one on the evidence. The case for it is that it is cheap, well tolerated, does not touch IGF-1 or glucose, and some people want to try it once and judge it against a tape measure. Community protocols report 250 to 500 mcg once daily in the morning for 8 to 12 weeks. Anyone buying it should know the 24 week trials in obese adults found no difference from placebo, and that it has been in FDA Category 2 since 2023.
Tesamorelin fits someone whose target is visceral belly fat specifically, who can afford an ongoing protocol, and who will check IGF-1 and fasting glucose. The label dose is 2 mg daily; community protocols report 1 to 2 mg, often at bedtime, with results judged at 12 to 26 weeks by waist measurement. It raises IGF-1 and can raise glucose in susceptible people, and the fat returns within months of stopping.
Tesamorelin is the only one of these two with evidence that it moves fat, and the evidence is specific: visceral fat, about 15 to 18 percent over six months, in people with HIV lipodystrophy, with the fat coming back after stopping. For someone without HIV the effect is less documented but seems to follow the same pattern, and it costs real money every month. AOD-9604 adds nothing demonstrated. The rodent lipolysis data are real, the human trials were run properly, and they found no weight loss. Vendors who stack AOD-9604 on top of tesamorelin are selling a second vial, not a second mechanism that has been shown to work. If total weight is the goal rather than visceral fat specifically, neither compound is the answer; the GLP-1 drugs have the trial data and are ranked at best peptides for weight loss. If growth hormone support rather than fat is the goal, the comparison that matters is tesamorelin vs ipamorelin. Both compounds here are prohibited by WADA, and this page is educational rather than a protocol.
Stacking: Some protocols add AOD-9604 on top of tesamorelin. There is no evidence the addition does anything, and no known interaction either. Tesamorelin is more often paired with ipamorelin for a larger growth hormone pulse.
AOD-9604 is a modified 16 amino acid fragment of the C-terminal end of human growth hormone, built to keep the fat burning signal of HGH without the growth or insulin effects. It lost its only real test: large phase 2 trials in obese adults found no meaningful weight loss, and the program was abandoned.
Tesamorelin is a stabilized growth hormone releasing hormone analog approved as Egrifta to reduce belly fat in people with HIV-related lipodystrophy. It is the GHRH analog with the strongest human evidence, and people use it off-label for visceral fat loss and general growth hormone support.
AOD-9604 vs Tesamorelin: frequently asked
Does AOD-9604 work for fat loss?
The best human evidence says no. An early 12 week study hinted at a small effect, but the larger 24 week phase 2b program in more than 500 obese adults found no meaningful weight loss versus placebo, and the company dropped the obesity indication in 2007. What the trials did establish is that it is well tolerated and does not raise IGF-1 or disturb glucose, which is the basis for its food ingredient safety status, not a benefit.
Is tesamorelin better than AOD-9604?
For fat, yes, without much of a contest. Tesamorelin has two phase 3 trials and an FDA approval showing about 15 to 18 percent visceral fat reduction over 26 weeks. AOD-9604 has a failed phase 2 program. The trade is that tesamorelin raises IGF-1, can raise blood glucose, costs more, and has to be continued to hold the result.
Can you stack AOD-9604 with tesamorelin?
People do, and there is no known interaction. There is also no evidence that AOD-9604 adds anything to tesamorelin alone, since it has not shown fat loss in people by itself. The pairing is a vendor and forum habit rather than a protocol with data. Tesamorelin is more usefully paired with ipamorelin, described at the tesamorelin and ipamorelin stack.
Is AOD-9604 the same as HGH fragment 176-191?
Almost. HGH fragment 176-191 is the raw 16 amino acid tail of growth hormone; AOD-9604 is that fragment with a tyrosine added at the front for stability. Vendors use the names interchangeably and the rodent data cover both. Neither binds the growth hormone receptor, which is why they do not raise IGF-1 and why they are not comparable to growth hormone itself.
Does tesamorelin work for people without HIV?
Probably in the same direction, with less documentation. The large trials were all in HIV lipodystrophy. Smaller studies in other groups point the same way, including a 12 month trial showing reduced liver fat and a 20 week trial reporting better executive function in older adults, neither replicated at scale. Off label use rests on that plus the mechanism, and the results are judged by waist measurement and IGF-1 at 3 to 6 months.
Are AOD-9604 and tesamorelin banned in sport?
Both are prohibited by WADA. AOD-9604 falls under S0, non approved substances, and several Australian footballers were sanctioned over it in 2013. Tesamorelin is prohibited as a growth hormone releasing factor. On the compounding side, AOD-9604 was placed in FDA Category 2 in 2023, while tesamorelin is an approved drug that can be prescribed off label; see the FDA peptide compounding list for 2026.
Related reading
Visceral fat loss with growth hormone support
An approved GHRH analog with fat loss trials versus the community's favorite GHRP.
Two GHRH analogs with approval histories. Which one still earns the price?
GLP-1
Guide
Buying
Sources
- Metabolic Pharmaceuticals phase 2b obesity trial results and discontinuation announcement. Metabolic Pharmaceuticals, ASX announcement, 2007
- Safety and tolerability of the hexadecapeptide AOD9604 in humans. Journal of Endocrinology and Metabolism, 2013
- Tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: pooled analysis of two Phase 3 trials. Journal of Acquired Immune Deficiency Syndromes, 2010
- Egrifta (tesamorelin for injection) prescribing information. US Food and Drug Administration, 2010